Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Edith A. Perez,
Sanne Lysbet de Haas,
Wolfgang Eiermann,
Carlos H. Barrios,
Masakazu Toi,
Young-Hyuck Im,
Pier Franco Conte,
Miguel Martin,
Tadeusz Pienkowski,
Xavier B. Pivot,
Howard A. Burris,
Sven Stanzel,
Monika Patre,
Paul Anthony Ellis
Affiliations
Edith A. Perez
Mayo Clinic
Sanne Lysbet de Haas
F. Hoffmann-La Roche Ltd
Wolfgang Eiermann
Interdisciplinary Oncology Center
Carlos H. Barrios
PUCRS School of Medicine
Masakazu Toi
Graduate School of Medicine, Kyoto University
Young-Hyuck Im
Samsung Medical Centre
Pier Franco Conte
Department of Surgery, Oncology and Gastroenterology, University of Padova and Istituto Oncologico Veneto
Miguel Martin
Instituto de Investigacion Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense
Tadeusz Pienkowski
Postgraduate Medical Education Center
Xavier B. Pivot
Paul Strauss Cancer Center, 3 Rue de la Porte de l’Hôpital
Howard A. Burris
Sarah Cannon Research Institute and Tennessee Oncology
